MARKET

RNA

RNA

Atrium Therapeutics, Inc
NASDAQ
13.19
+0.41
+3.21%
After Hours: 13.19 0 0.00% 19:00 06/26 EDT
OPEN
12.78
PREV CLOSE
12.78
HIGH
13.20
LOW
12.72
VOLUME
758.71K
TURNOVER
--
52 WEEK HIGH
16.77
52 WEEK LOW
11.40
MARKET CAP
225.62M
P/E (TTM)
-4.9312
1D
5D
1M
3M
1Y
5Y
1D
Atrium Therapeutics grants 8 new hires stock awards including 66,000 options at $12.66
PUBT · 4d ago
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR Newswire · 4d ago
Weekly Report: what happened at RNA last week (0615-0619)?
Weekly Report · 6d ago
Avidity Biosciences Initiated at Overweight by Cantor Fitzgerald
Dow Jones · 06/18 13:00
Avidity Biosciences Price Target Announced at $25.00/Share by Cantor Fitzgerald
Dow Jones · 06/18 13:00
Cantor Fitzgerald Initiates Coverage On Atrium Therapeutics with Overweight Rating, Announces Price Target of $25
Benzinga · 06/18 12:50
Atrium Therapeutics initiated with an Overweight at Cantor Fitzgerald
TipRanks · 06/18 10:12
We're Hopeful That Atrium Therapeutics (NASDAQ:RNA) Will Use Its Cash Wisely
Simply Wall St · 06/16 11:02
More
About RNA
Atrium Therapeutics, Inc. is a biopharmaceutical company engaged in the delivery of ribonucleic acid (RNA) therapeutics for people living with cardiomyopathy. Its technology leverages the targeted RNA delivery platform, which combines the tissue selectivity of monoclonal antibodies (mAbs) and other targeted delivery ligands with oligonucleotides. It is designed to allow selective targeting of the underlying genetic drivers of disease. Its development pipeline consists of programs that target genetically validated drivers of cardiomyopathy, which include Protein Kinase AMP-Activated Non-Catalytic Subunit Gamma 2 (PRKAG2) and Phospholamban (PLN). Its genetic drivers are associated with PRKAG2 syndrome and PLN cardiomyopathy, which is a genetic heart condition associated with life-threatening forms of heart disease. Its programs are supported by preclinical data, in addition to positive clinical data generated in neuromuscular indications using the same RNA delivery platform technology.

Webull offers Atrium Therapeutics Inc stock information, including NASDAQ: RNA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RNA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RNA stock methods without spending real money on the virtual paper trading platform.